Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer.

Yu PP, Eton O, Garrison LP.

J Immunother Cancer. 2019 Sep 3;7(1):235. doi: 10.1186/s40425-019-0707-9.

2.

Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAFV600E Mutated Papillary Thyroid Cancer: Two Case Reports.

White PS, Pudusseri A, Lee SL, Eton O.

Thyroid. 2017 Sep;27(9):1201-1205. doi: 10.1089/thy.2017.0106.

3.

Melanoma brain metastasis: overview of current management and emerging targeted therapies.

Fonkem E, Uhlmann EJ, Floyd SR, Mahadevan A, Kasper E, Eton O, Wong ET.

Expert Rev Neurother. 2012 Oct;12(10):1207-15. doi: 10.1586/ern.12.111. Review.

PMID:
23082737
4.

Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics.

Macarulla T, Cervantes A, Elez E, Rodríguez-Braun E, Baselga J, Roselló S, Sala G, Blasco I, Danaee H, Lee Y, Ecsedy J, Shinde V, Chakravarty A, Bowman D, Liu H, Eton O, Fingert H, Tabernero J.

Mol Cancer Ther. 2010 Oct;9(10):2844-52. doi: 10.1158/1535-7163.MCT-10-0299. Epub 2010 Aug 19.

5.

Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors.

Dees EC, Infante JR, Cohen RB, O'Neil BH, Jones S, von Mehren M, Danaee H, Lee Y, Ecsedy J, Manfredi M, Galvin K, Stringer B, Liu H, Eton O, Fingert H, Burris H.

Cancer Chemother Pharmacol. 2011 Apr;67(4):945-54. doi: 10.1007/s00280-010-1377-y. Epub 2010 Jul 7.

6.

Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma.

Eton O, Ross MI, East MJ, Mansfield PF, Papadopoulos N, Ellerhorst JA, Bedikian AY, Lee JE.

J Transl Med. 2010 Jan 29;8:9. doi: 10.1186/1479-5876-8-9.

7.

A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer.

Lynch TJ, Fenton D, Hirsh V, Bodkin D, Middleman EL, Chiappori A, Halmos B, Favis R, Liu H, Trepicchio WL, Eton O, Shepherd FA.

J Thorac Oncol. 2009 Aug;4(8):1002-9. doi: 10.1097/JTO.0b013e3181aba89f.

8.

A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence.

Kim KB, Legha SS, Gonzalez R, Anderson CM, Johnson MM, Liu P, Papadopoulos NE, Eton O, Plager C, Buzaid AC, Prieto VG, Hwu WJ, Frost AM, Alvarado G, Hwu P, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Benjamin RS, Bedikian AY.

Melanoma Res. 2009 Feb;19(1):42-9. doi: 10.1097/CMR.0b013e328314b84a.

PMID:
19430405
9.

Phase II trial of imatinib mesylate in patients with metastatic melanoma.

Kim KB, Eton O, Davis DW, Frazier ML, McConkey DJ, Diwan AH, Papadopoulos NE, Bedikian AY, Camacho LH, Ross MI, Cormier JN, Gershenwald JE, Lee JE, Mansfield PF, Billings LA, Ng CS, Charnsangavej C, Bar-Eli M, Johnson MM, Murgo AJ, Prieto VG.

Br J Cancer. 2008 Sep 2;99(5):734-40. doi: 10.1038/sj.bjc.6604482. Epub 2008 Aug 19.

10.

Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment.

Hwang CS, Prieto VG, Diwan AH, Lizee G, Ellerhorst JA, Ekmekcioglu S, Liu P, Eton O, Kinney SA, Grimm EA, Hwu P, Kim KB.

Melanoma Res. 2008 Aug;18(4):241-5. doi: 10.1097/CMR.0b013e3283046146.

11.

Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).

Ivan D, Niveiro M, Diwan AH, Eton O, Kim KB, Lacey C, Gonzalez C, Prieto VG.

J Cutan Pathol. 2006 Apr;33(4):280-5.

PMID:
16630177
12.

Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.

Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F, Byrnes C, Sanders K, Sosman JA.

Cancer. 2006 May 1;106(9):2005-11.

13.

Chemotherapy, cytokines, and biochemotherapy for melanoma.

Eton O.

Cancer Chemother Biol Response Modif. 2005;22:739-48. Review. No abstract available.

PMID:
16110637
14.

Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma.

Kim KB, Eton O, East MJ, Hodges C, Papadopoulos NE, Grimm EA, Bedikian AY.

Cancer. 2004 Aug 1;101(3):596-603.

15.

Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma.

Bedikian AY, Plager C, Papadopoulos N, Eton O, Ellerhorst J, Smith T.

Melanoma Res. 2004 Feb;14(1):63-6.

PMID:
15091196
16.

Biochemotherapy in patients with metastatic anorectal mucosal melanoma.

Kim KB, Sanguino AM, Hodges C, Papadopoulos NE, Eton O, Camacho LH, Broemeling LD, Johnson MM, Ballo MT, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Prieto VG, Bedikian AY.

Cancer. 2004 Apr 1;100(7):1478-83.

17.

Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.

McGary EC, Onn A, Mills L, Heimberger A, Eton O, Thomas GW, Shtivelband M, Bar-Eli M.

J Invest Dermatol. 2004 Feb;122(2):400-5.

18.

Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array.

Shen SS, Zhang PS, Eton O, Prieto VG.

J Cutan Pathol. 2003 Oct;30(9):539-47.

PMID:
14507401
19.

Phase II evaluation of temozolomide in metastatic choroidal melanoma.

Bedikian AY, Papadopoulos N, Plager C, Eton O, Ring S.

Melanoma Res. 2003 Jun;13(3):303-6.

PMID:
12777987
20.

Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma.

Eton O, Rosenblum MG, Legha SS, Zhang W, Jo East M, Bedikian A, Papadopoulos N, Buzaid A, Benjamin RS.

Cancer. 2002 Jul 1;95(1):127-34.

21.

Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.

Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, Ring SE, Papadopoulos NE, Plager C, East MJ, Zhan F, Benjamin RS.

J Clin Oncol. 2002 Apr 15;20(8):2045-52.

PMID:
11956264
22.

Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma.

Ellerhorst JA, Bedikian AY, Smith TM, Papadopoulos NE, Plager C, Eton O.

Anticancer Drugs. 2002 Feb;13(2):169-72.

PMID:
11901310
23.

Phase II evaluation of bryostatin-1 in metastatic melanoma.

Bedikian AY, Plager C, Stewart JR, O'Brian CA, Herdman SK, Ross M, Papadopoulos N, Eton O, Ellerhorst J, Smith T.

Melanoma Res. 2001 Apr;11(2):183-8.

PMID:
11333129
24.

Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy.

Grimm EA, Smid CM, Lee JJ, Tseng CH, Eton O, Buzaid AC.

Clin Cancer Res. 2000 Oct;6(10):3895-903.

25.

A phase II study of "decrescendo" interleukin-2 plus interferon-alpha-2a in patients with progressive metastatic melanoma after chemotherapy.

Eton O, Buzaid AC, Bedikian AY, Smith TM, Papadopoulos NE, Ellerhorst JA, Hibberts JL, Legha SS, Benjamin RS.

Cancer. 2000 Apr 1;88(7):1703-9.

PMID:
10738230
26.

Pilot study of intra-arterial cisplatin and intravenous vinblastine and dacarbazine in patients with melanoma in-transit metastases.

Eton O, East M, Legha SS, Bedikian A, Buzaid AC, Papadopoulos N, Hodges C, Gianan M, Carrasco CH, Benjamin RS.

Melanoma Res. 1999 Oct;9(5):483-9.

PMID:
10596915
27.

Phase II trial of escalated dose of tirapazamine combined with cisplatin in advanced malignant melanoma.

Bedikian AY, Legha SS, Eton O, Buzaid AC, Papadopoulos N, Plager C, McIntyre S, Viallet J.

Anticancer Drugs. 1999 Sep;10(8):735-9.

PMID:
10573206
28.

Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy.

Ellerhorst JA, Bedikian A, Ring S, Buzaid AC, Eton O, Legha SS.

Oncol Rep. 1999 Sep-Oct;6(5):1097-9.

PMID:
10425308
29.

Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases.

Buzaid AC, Colome M, Bedikian A, Eton O, Legha SS, Papadopoulos N, Plager C, Ross M, Lee JE, Mansfield P, Rice J, Ring S, Lee JJ, Strom E, Benjamin R.

Melanoma Res. 1998 Dec;8(6):549-56.

PMID:
9918417
30.

Enhancement of cell-mediated immunity in melanoma patients immunized with murine anti-idiotypic monoclonal antibodies (MELIMMUNE) that mimic the high molecular weight proteoglycan antigen.

Pride MW, Shuey S, Grillo-Lopez A, Braslawsky G, Ross M, Legha SS, Eton O, Buzaid A, Ioannides C, Murray JL.

Clin Cancer Res. 1998 Oct;4(10):2363-70.

31.

Hypercalcemia due to parathyroid hormone-related protein secretion by melanoma.

Yeung SC, Eton O, Burton DW, Deftos LJ, Vassilopoulou-Sellin R, Gagel RF.

Horm Res. 1998;49(6):288-91.

PMID:
9623520
32.

Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy.

Anderson CM, Buzaid AC, Sussman J, Lee JJ, Ali-Osman F, Braunschweiger PG, Plager C, Bedikian A, Papadopoulos N, Eton O, Legha SS, Grimm EA.

Melanoma Res. 1998 Apr;8(2):149-55.

PMID:
9610868
33.

DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma.

Buzaid AC, Ali-Osman F, Akande N, Grimm EA, Lee JJ, Bedikian A, Eton O, Papadopoulos N, Plager C, Legha SS, Benjamin RS.

Melanoma Res. 1998 Apr;8(2):145-8.

PMID:
9610867
34.
35.

Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.

Eton O, Kharkevitch DD, Gianan MA, Ross MI, Itoh K, Pride MW, Donawho C, Buzaid AC, Mansfield PF, Lee JE, Legha SS, Plager C, Papadopoulos NE, Bedikian AY, Benjamin RS, Balch CM.

Clin Cancer Res. 1998 Mar;4(3):619-27.

36.

Prognostic factors for survival of patients treated systemically for disseminated melanoma.

Eton O, Legha SS, Moon TE, Buzaid AC, Papadopoulos NE, Plager C, Burgess AM, Bedikian AY, Ring S, Dong Q, Glassman AB, Balch CM, Benjamin RS.

J Clin Oncol. 1998 Mar;16(3):1103-11.

PMID:
9508197
37.

Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience.

Legha SS, Ring S, Eton O, Bedikian A, Plager C, Papadopoulos N.

Cancer J Sci Am. 1997 Dec;3 Suppl 1:S9-15.

PMID:
9457387
38.

Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma.

Bedikian AY, Legha SS, Eton O, Buzaid AC, Papadopoulos N, Coates S, Simmons T, Neefe J, von Roemeling R.

Ann Oncol. 1997 Apr;8(4):363-7.

39.

Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system.

Buzaid AC, Ross MI, Balch CM, Soong S, McCarthy WH, Tinoco L, Mansfield P, Lee JE, Bedikian A, Eton O, Plager C, Papadopoulos N, Legha SS, Benjamin RS.

J Clin Oncol. 1997 Mar;15(3):1039-51.

PMID:
9060544
40.
41.

Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma.

Murray JL, Kleinerman ES, Jia SF, Rosenblum MG, Eton O, Buzaid A, Legha S, Ross MI, Thompson L, Mujoo K, Rieger PT, Saleh M, Khazaeli MB, Vadhan-Raj S.

J Immunother Emphasis Tumor Immunol. 1996 May;19(3):206-17.

PMID:
8811495
42.

Phase II trial of recombinant human interleukin-2 and interferon-alpha-2a: implications for the treatment of patients with metastatic melanoma.

Eton O, Talpaz M, Lee KH, Rothberg JM, Brell JM, Benjamin RS.

Cancer. 1996 Mar 1;77(5):893-9.

PMID:
8608480
43.

Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma.

Legha SS, Gianan MA, Plager C, Eton OE, Papadopoulous NE.

Cancer. 1996 Jan 1;77(1):89-96.

PMID:
8630945
44.

Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy.

Bedikian AY, Weiss GR, Legha SS, Burris HA 3rd, Eckardt JR, Jenkins J, Eton O, Buzaid AC, Smetzer L, Von Hoff DD, et al.

J Clin Oncol. 1995 Dec;13(12):2895-9.

PMID:
8523052
45.

Interleukin-1 production in tumor cells of human melanoma surgical specimens.

Tyler DS, Francis GM, Frederick M, Tran AH, Ordóñez NG, Smith JL, Eton O, Ross M, Grimm EA.

J Interferon Cytokine Res. 1995 Apr;15(4):331-40.

PMID:
7627808
46.

Mechanism of the anti-tumour effect of biochemotherapy in melanoma: preliminary results.

Buzaid AC, Grimm EA, Ali-Osman F, Ring S, Eton O, Papadopoulos NE, Bedikian A, Plager C, Legha SS, Benjamin R.

Melanoma Res. 1994 Oct;4(5):327-30.

PMID:
7858418
47.

Increase in the ability of human cancer cells to induce cytotoxic T lymphocytes by ultraviolet irradiation.

Umezu Y, Augustus LB, Seito D, Hayakawa K, Ross MI, Eton O, Swanson DA, Itoh K.

Cancer Immunol Immunother. 1993 Nov;37(6):392-9.

PMID:
8242664
48.

Cutaneous melanoma.

Eton O, Legha SS, Balch CM.

N Engl J Med. 1992 Jan 30;326(5):345-6; author reply 346-7. No abstract available.

PMID:
1728744
49.

Phase II trial of N-methylformamide in patients with metastatic melanoma.

Eton O, Bajorin DF, Casper ES, Houghton AN.

Invest New Drugs. 1991 Feb;9(1):97-100.

PMID:
2026491
50.

Phase II trial of cisplatin and etoposide in patients with metastatic melanoma.

Eton O, Bajorin DF, Chapman PB, Cody BV, Houghton AN.

Invest New Drugs. 1991 Feb;9(1):101-3.

PMID:
2026478

Supplemental Content

Support Center